PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI
PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI
Active, not recruiting · NCT05457582 · Registry updated 2026-07-21Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| PCSK 9 Inhibitor Added to High-Intensity Statin Therapy to Prevent Cardiovascular Events in Patients With ACS After PCI | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, acute coronary syndrome, cardiovascular disorder, heart disorder, hyperlipidemia, metabolic disease, myocardial ischemia, vascular disorder | Active, not recruiting | Not applicable | 2026-07-21 | NCT05457582 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Nanjing First Hospital, Nanjing Medical University | 96 |
| Nanjing Medical University | 58 |
| National Natural Science Foundation of China | 35 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nanjing First Hospital | Nanjing | China | 47 |